Leading AI stroke platform developer aims to speed clinical trial enrollment
Viz.ai has announced the launch of Viz RECRUIT, cutting edge software that uses artificial intelligence to accelerate clinical studies. Viz RECRUIT uses AI to automatically detect a suspected disease such as a brain hemorrhage, a tumor, or a cardiac structural abnormality, and uses that insight to ensure the right doctor is notified about the patient. This improves workflow and expedites enrollment in trials. Viz RECRUIT alerts research teams about potentially eligible trial patients across an entire health system and enables easy communication between clinical teams, research teams, principal investigators, and core labs to facilitate enrollment.
“Viz RECRUIT is how clinical trials should be run. We are able to be alerted to potential patients and quickly move them to enrollment and treatment. I hope we can use Viz RECRUIT for all of our other clinical studies.”
Clinical trials are used to approve new procedures, devices, and drugs as standards of care. These studies can take years and upwards of millions of dollars to complete as research teams are challenged to first identify, then enroll patients meeting specific enrollment criteria. Viz.ai developed Viz RECRUIT to address these challenges. The first industry sponsored clinical study to use Viz RECRUIT is the ENRICH trial, sponsored by NICO Corp., investigating minimally invasive hematoma extraction for intracranial hemorrhage patients. One site, University of Buffalo, that now uses Viz RECRUIT enrolled at 3.3 times the rate than without Viz RECRUIT, and was described by investigators like Dr. Adnan Siddiqui as the “future of clinical trials.”
Recommended AI News: Cognira Makes Its AI-Powered Promotion Suite Available to All Retailers
Jim Pearson, CEO of Nico Corp., said, “The initial ENRICH sites that have enabled Viz RECRUIT are picking up enrollment velocity. There is immense value to both the patient and industry in potentially completing trials in less time and with better efficiency. We are excited to see Viz RECRUIT continue to grow in its market utilization.”
Recommended AI News: Ease and Reliance Standard Launch Unique Integration Partnership
Dr. Brian Jankowitz, Neurosurgeon and Director of Cerebrovascular Program at Cooper University Health Care, and an ENRICH investigator, added, “Viz RECRUIT is how clinical trials should be run. We are able to be alerted to potential patients and quickly move them to enrollment and treatment. I hope we can use Viz RECRUIT for all of our other clinical studies.”
Viz RECRUIT is becoming the standard for neurovascular clinical trials, and there are several new additional clinical trials that will begin enrolling later this year.
Recommended AI News: Supermicro Introduces NVIDIA GPU Server Test Drive Program
Copper scrap market trends Copper scrap logistics Scrap metal reclamation and utilization center
Selling Copper cable scrap, Metal reclaiming Yard, Copper scrap recycling infrastructure